Cassava Sciences (SAVA) Short Interest Ratio & Short Volume → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free SAVA Stock Alerts $22.34 +0.61 (+2.81%) (As of 04/26/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Cassava Sciences Short Interest DataCurrent Short Volume12,840,000 sharesPrevious Short Volume11,790,000 sharesChange Vs. Previous Month+8.91%Dollar Volume Sold Short$256.93 millionShort Interest Ratio / Days to Cover17.7Last Record DateApril 15, 2024Outstanding Shares43,250,000 sharesPercentage of Shares Shorted29.69%Today's Trading Volume1,072,429 sharesAverage Trading Volume769,982 sharesToday's Volume Vs. Average139% Short Selling Cassava Sciences ? Sign up to receive the latest short interest report for Cassava Sciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatSAVA Short Interest Over TimeSAVA Days to Cover Over TimeSAVA Percentage of Float Shorted Over Time Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. Cassava Sciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202412,840,000 shares $256.93 million +8.9%N/A17.7 $20.01 3/31/202411,790,000 shares $239.22 million -1.4%N/A17 $20.29 3/15/202411,960,000 shares $254.63 million +5.7%30.5%15.7 $21.29 2/29/202411,320,000 shares $260.13 million -3.7%28.9%11.4 $22.98 2/15/202411,760,000 shares $288.94 million -3.5%30.7%12.3 $24.57 1/31/202412,180,000 shares $291.71 million -8.6%31.8%11.5 $23.95 Get the Latest News and Ratings for SAVA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. 1/15/202413,330,000 shares $349.78 million -4.0%33.6%10.2 $26.24 12/31/202313,890,000 shares $312.66 million +8.9%35.0%9.2 $22.51 12/15/202312,760,000 shares $268.96 million -7.0%32.2%8.6 $21.08 11/30/202313,720,000 shares $285.79 million -5.8%34.7%11.2 $20.83 11/15/202314,560,000 shares $317.70 million -8.9%36.8%11.3 $21.82 10/31/202315,990,000 shares $322.20 million +14.1%40.6%12.4 $20.15 10/15/202314,020,000 shares $208.34 million -1.3%35.6%13.1 $14.86 9/30/202314,210,000 shares $236.45 million +3.7%36.1%17.2 $16.64 9/15/202313,700,000 shares $265.92 million +2.7%34.8%14.8 $19.41 8/31/202313,340,000 shares $279.74 million +8.8%33.9%14.8 $20.97 8/15/202312,260,000 shares $215.16 million +7.3%31.1%14.9 $17.55 7/31/202311,430,000 shares $251.23 million +2.1%29.0%13.4 $21.98 7/15/202311,200,000 shares $242.26 million +10.5%28.6%13.9 $21.63 6/30/202310,140,000 shares $248.63 million +8.1%25.9%13 $24.52 6/15/20239,380,000 shares $235.16 million -13.2%23.9%14.4 $25.07 5/31/202310,800,000 shares $245.27 million +6.3%27.6%15.2 $22.71 5/15/202310,160,000 shares $269.34 million -7.5%25.9%14.4 $26.51 4/30/202310,980,000 shares $254.96 million -0.6%28.0%14.5 $23.22 4/15/202311,050,000 shares $257.69 million -3.9%28.2%10.1 $23.32 3/31/202311,500,000 shares $277.38 million +9.9%30.0%9.7 $24.12 3/15/202310,460,000 shares $272.48 million -5.0%27.3%7.9 $26.05 2/28/202311,010,000 shares $271.95 million +3.9%28.7%7.9 $24.70 2/15/202310,600,000 shares $279.95 million +7.6%27.6%7.6 $26.41 1/31/20239,850,000 shares $275.80 million -4.6%25.1%6.4 $28.00 1/15/202310,320,000 shares $350.88 million +18.8%26.3%7.3 $34.00 12/30/20228,690,000 shares $256.70 million -1.3%22.1%7 $29.54 12/15/20228,800,000 shares $348.22 million -5.7%22.4%5.6 $39.57 11/30/20229,330,000 shares $324.96 million No Change23.8%4 $34.83 11/15/20229,330,000 shares $374.13 million -0.4%23.8%3.7 $40.10 10/31/20229,370,000 shares $341.44 million -2.7%24.9%2.8 $36.44 10/15/20229,630,000 shares $351.11 million -10.7%25.6%2.6 $36.46 9/30/202210,780,000 shares $450.82 million -14.1%N/A2.9 $41.82 9/15/202212,550,000 shares $396.33 million -0.2%N/A3.7 $31.58 8/31/202212,580,000 shares $323.68 million +4.4%N/A5.1 $25.73Move Your Money Before May 1 (Ad)Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. SAVA Short Interest - Frequently Asked Questions What is Cassava Sciences' current short interest? Short interest is the volume of Cassava Sciences shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 12,840,000 shares of SAVA short. Learn More on Cassava Sciences' current short interest. What is a good short interest ratio for Cassava Sciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SAVA shares currently have a short interest ratio of 18.0. Learn More on Cassava Sciences's short interest ratio. Which institutional investors are shorting Cassava Sciences? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cassava Sciences: Simplex Trading LLC, Cantor Fitzgerald L. P., IMC Chicago LLC, Concourse Financial Group Securities Inc., National Bank of Canada FI, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Cassava Sciences' short interest increasing or decreasing? Cassava Sciences saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 12,840,000 shares, an increase of 8.9% from the previous total of 11,790,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Cassava Sciences' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Cassava Sciences: Zentalis Pharmaceuticals, Inc. (23.45%), Immunome, Inc. (4.44%), OPKO Health, Inc. (23.81%), Tyra Biosciences, Inc. (13.78%), 89bio, Inc. (11.77%), Arcutis Biotherapeutics, Inc. (20.31%), Centessa Pharmaceuticals plc (2.14%), Tango Therapeutics, Inc. (19.37%), ARS Pharmaceuticals, Inc. (14.44%), Innoviva, Inc. (18.46%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Cassava Sciences stock? Short selling SAVA is an investing strategy that aims to generate trading profit from Cassava Sciences as its price is falling. SAVA shares are trading up $0.43 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cassava Sciences? A short squeeze for Cassava Sciences occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of SAVA, which in turn drives the price of the stock up even further. How often is Cassava Sciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SAVA, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Zentalis Pharmaceuticals Short Interest Data Immunome Short Interest Data OPKO Health Short Interest Data Tyra Biosciences Short Interest Data 89bio Short Interest Data Arcutis Biotherapeutics Short Interest Data Centessa Pharmaceuticals Short Interest Data Tango Therapeutics Short Interest Data ARS Pharmaceuticals Short Interest Data Innoviva Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SAVA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press